Potential role of 1,25(OH)2 vitamin D3 as a dose-reducing agent for cyclosporine and FK 506.
Mathieu
C
C
Laboratory of Immunopathology, Rega Institute, K.U. Leuven, Belgium.
Bouillon
R
R
Rutgeerts
O
O
Vandeputte
M
M
Waer
M
M
D002117:Calcitriol / Q000494:pharmacology*; D002478:Cells, Cultured; D016572:Cyclosporine / Q000494:pharmacology*; D016207:Cytokines / Q000032:analysis / Q000096:biosynthesis*; D004347:Drug Interactions; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007371:Interferon-gamma / Q000096:biosynthesis; D007375:Interleukin-1 / Q000096:biosynthesis; D007376:Interleukin-2 / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis; D007959:Lymphocyte Culture Test, Mixed; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*; D016559:Tacrolimus / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D016207:Cytokines; D007166:Immunosuppressive Agents; D007375:Interleukin-1; D007376:Interleukin-2; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D016572:Cyclosporine; D002117:Calcitriol; D016559:Tacrolimus